---
title: "诺和诺德欧股开盘跌 4.4%，白宫据悉将就诺和诺德的 Ozempic 之类的减肥药进行谈判，以获得更低的价格。"
description: "诺和诺德欧股开盘跌 4.4%，白宫据悉将就诺和诺德的 Ozempic 之类的减肥药进行谈判，以获得更低的价格。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261562759.md"
published_at: "2025-10-17T07:05:41.000Z"
---

# 诺和诺德欧股开盘跌 4.4%，白宫据悉将就诺和诺德的 Ozempic 之类的减肥药进行谈判，以获得更低的价格。

诺和诺德欧股开盘跌 4.4%，白宫据悉将就诺和诺德的 Ozempic 之类的减肥药进行谈判，以获得更低的价格。

### Related Stocks

- [NVO.US - 诺和诺德公司](https://longbridge.com/zh-CN/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Biocon aims for revenue surge with rollout of generic weight-loss drugs | Biocon aims for high double-digit revenue growth with the global launch of generic weight-loss drugs, including versions | [Link](https://longbridge.com/zh-CN/news/275900960.md) |
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/zh-CN/news/276056741.md) |
| Correction to Novo Nordisk TV Ad Article on Feb. 9 | Angela Muñoz is director of regulatory affairs at Novo Nordisk. "Novo Nordisk TV Ad for Oral Wegovy Has Misleading Claim | [Link](https://longbridge.com/zh-CN/news/275669553.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/zh-CN/news/276280378.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/zh-CN/news/275719942.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。